<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Nina Kjellson on Medium]]></title>
        <description><![CDATA[Stories by Nina Kjellson on Medium]]></description>
        <link>https://medium.com/@ninakjellson?source=rss-c1d9c296707f------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*9R74iFT0W21jjihN.jpg</url>
            <title>Stories by Nina Kjellson on Medium</title>
            <link>https://medium.com/@ninakjellson?source=rss-c1d9c296707f------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 15:06:41 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@ninakjellson/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Why I’m Excited To Help Reinvent Treatment for Heavy Drinking]]></title>
            <link>https://medium.com/canaan-partners/why-im-excited-to-help-reinvent-treatment-for-heavy-drinking-c4956bd1368c?source=rss-c1d9c296707f------2</link>
            <guid isPermaLink="false">https://medium.com/p/c4956bd1368c</guid>
            <category><![CDATA[annum-health]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Nina Kjellson]]></dc:creator>
            <pubDate>Tue, 08 Aug 2017 20:46:51 GMT</pubDate>
            <atom:updated>2017-08-10T18:13:16.131Z</atom:updated>
            <content:encoded><![CDATA[<p>It’s hard to think of an issue where innovation has lagged further behind the scope of a problem than that of heavy drinking. That’s why I’m so proud that Canaan is backing <a href="https://www.annum.com/">Annum Health</a> to provide a transformative new solution for heavy drinking.</p><p><em>A Problem of Epic Proportions</em></p><p>For far too many, the relationship with alcohol is complex, painful and sticky. We see this play out everywhere in our own lives: quick shots to ease anxiety at a party; three glasses of wine to downshift a spinning mind before bed; the third or fourth cocktail to celebrate a business win; beers to toast the weekend after a stressful week. TV and movies re-enforce. Social media documents and normalizes.</p><p>Taken collectively, millions of people feel shame, fogginess, pain, low motivation and lack of sleep the next day. Really, <a href="https://www.niaaa.nih.gov/alcohol-facts-and-statistics"><em>millions</em></a>. One in four U.S. adults binge drink, 32 million engage in “extreme binge drinking” and 16 million people actually meet the clinical criteria for <a href="https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-use-disorders">Alcohol Use Disorder</a>.</p><p>Not only does this represent a crisis of wellbeing for individuals, families and communities, but it is also a costly epidemic for society: heavy drinking costs the U.S. economy $250 billion per year — almost a third of that due to lost workplace productivity, as most heavy drinkers are employed. Alcohol use and abuse has shot up since 2001 according to an in-depth <a href="https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2647079">study</a> published by JAMA Psychiatry and reported by <a href="https://www.bloomberg.com/news/articles/2017-08-09/america-s-drinking-problem-is-much-worse-this-century">Bloomberg</a>.</p><p><em>A Welcome Disruption</em></p><p>It’s stunning that the $35 billion rehab industry thrives, even as consumer and health plan sponsors find these options so unsatisfactory that only 10% of people in need of treatment receive it.</p><p>It’s true: <a href="https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015.htm#tab5-56a">nine out of ten people in need of treatment for a substance use disorder</a> don’t even consider getting professional help, and for fair-minded reasons. Rehab is a huge disruption to personal and professional life. Quality therapists often have high out of pocket costs and limited appointment times. The local in-person group programs may not feel like a good fit. Most heavy drinkers haven’t hit “rock bottom”, so, far too many people in need continue to be unserved and unsupported.</p><p>Make no mistake: people want to change! Just look at Reddit’s 75,000-member strong community <a href="https://www.reddit.com/r/stopdrinking/">StopDrinking</a>. What’s more, health plans and employers want to offer good solutions to their covered individuals. As we weighed our investment with Annum, I was stunned by how many market due diligence calls with national health plans and self-insured employers centered around the same question. Not whether the problem exists, not whether the Annum solution made sense, but rather: “how quickly can you get me this new solution?”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*wm6UOvhWItv1gii_K7Hj_Q.jpeg" /></figure><p><em>Annum’s Innovative Solution</em></p><p>If one thing’s clear, it’s the need for an alternative to rehab for heavy drinking, and that alternative is Annum Health.</p><p>Annum’s <a href="https://www.annum.com/who-we-are/">reinvented health-tech model</a> casts every outdated assumption about rehab aside. Instead of centering treatment around 12-step facilitation, Annum deploys a physician, counselor and coach for each participant. This highly-trained, multi-pronged treatment team delivers an evidence-based suite of treatment that includes therapy, medicine, education, coaching and peer support in a private, highly personalized and mobile-enabled way.</p><p>Unlike a 28-day stay in a bricks and mortar rehab facility, Annum’s program lasts up to a year, is far more affordable and is offered proactively to all members of a sponsor’s population to reduce stigma and hassle. Benefits are measured the way we ourselves measure our own success — in terms of quality of life enhancements, reduced heavy drinking episodes and increased performance at work — rather than simply by days, weeks and years sober. In fact, a person can get treatment at Annum — and be considered a success story — even if they don’t give up drinking forever.</p><p><em>An Investment to be Proud Of</em></p><p>With every investment in digital health, Canaan looks at areas where current solutions are ineffective or where barriers put effective products and services out of reach of people who are most in need. We also weigh the experience and credibility of the team and like to bet on been-there, done-that entrepreneurs. Annum has all of this in spades.</p><p>Annum’s CEO, <a href="https://www.linkedin.com/in/michael-b-laskoff-7410bb1/">Michael Laskoff</a>, founded <a href="https://www.ableto.com/">AbleTo</a>, a successful and still-growing behavioral health company providing clinical and peer support for individuals with mental health diagnoses on top of another serious medical condition. Recognizing that heavy drinking was a problem in need of a totally new solution, his explorations — like my own — led him to interview the leading experts in the field, including <a href="https://www.linkedin.com/in/mark-willenbring-m-d-ab993a12/">Dr. Mark Willenbring</a>, a 35-year veteran in alcohol treatment and addiction research, who quickly became a collaborator (you can read more about Mark <a href="http://alltyr.com/dr-w/">here</a> and <a href="https://www.nytimes.com/2016/02/23/science/mark-willenbring-addiction-substance-abuse-treatment.html">here</a>). To merge the best of research and medical practice with the most advanced patient- and provider-facing technologies, they synched up with a third co-founder, Stanford and Mayo Clinic-trained, <a href="https://www.linkedin.com/in/ljwolfe/">Dr. Lauren Wolfe</a>.</p><p>Together, the team hatched a technology solution, a consumer-centric approach and B2B distribution model and set about to find seed funding. It is pretty telling that the seed round came together in a similarly deliberate way: a global insurance company, AXA Strategic Ventures, as a strategic anchor; a digital health <em>and</em> biopharma VC to bring the interdisciplinary angle (me); plus a repeat backer, .406 Ventures, who previously helped Michael get AbleTo off the ground. In short order, Annum has built a full leadership team, developed its initial product offering and signed its first large health plan partner, with others on the way.</p><p>Annum is a startup on a mission to tackle a major source of individual and social suffering. Cheers to that (pun intended).</p><p><a href="https://www.annum.com/partner-with-us/">Read more about how Annum is different from the status quo here.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c4956bd1368c" width="1" height="1" alt=""><hr><p><a href="https://medium.com/canaan-partners/why-im-excited-to-help-reinvent-treatment-for-heavy-drinking-c4956bd1368c">Why I’m Excited To Help Reinvent Treatment for Heavy Drinking</a> was originally published in <a href="https://medium.com/canaan-partners">Canaan</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Roadmap for Increasing Diversity in Boardrooms]]></title>
            <link>https://medium.com/canaan-partners/the-roadmap-for-increasing-diversity-in-boardrooms-a5e011135f54?source=rss-c1d9c296707f------2</link>
            <guid isPermaLink="false">https://medium.com/p/a5e011135f54</guid>
            <category><![CDATA[diversity]]></category>
            <dc:creator><![CDATA[Nina Kjellson]]></dc:creator>
            <pubDate>Mon, 24 Jul 2017 17:39:22 GMT</pubDate>
            <atom:updated>2017-07-24T17:39:22.218Z</atom:updated>
            <content:encoded><![CDATA[<p>When we embark on a journey, many of us start by looking at a map to our destination. It might be a physical, paper map or, increasingly, some sort of electronic guide. The map shows us our start and end points, and options for getting where we want to go. It might not have the romance of navigating by the stars, but there is little chance that we will lose our way and not make it to our journey’s end.</p><p>But within so many companies that supposedly want to increase the diversity in their boardrooms, there is no map, no documented plan for making the changes that most so desperately need. It is possible to create one, however, by taking six straightforward steps when a company is first being created or — failing that — before it goes for an initial public offering (IPO).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*1v73bcBObdPMdSrpCJZmQA.jpeg" /></figure><p>Diversity is not a matter of window dressing. It is something that every company should want because boardroom diversity is a positive predictor of effective governance. Diverse boards have better dialogue, more strategic engagement, and more dynamic and transparent interactions with management teams. When boards better reflect a company’s own organizational composition — and the composition of the start-up industry (and markets) as a whole — they become more inclusive and accountable. Beyond the cultural benefits (and being the right thing to do), there is incontrovertible evidence that companies with diverse boards <a href="http://www.mckinsey.com/business-functions/organization/our-insights/is-there-a-payoff-from-top-team-diversity">deliver better financial results.</a></p><p>How to build that diverse board? Here’s my map:</p><p><strong>Demand diversity for independent directors. </strong>Eight of ten founders (<a href="http://techcrunch.com/2017/04/19/in-2017-only-17-of-startups-have-a-female-founder/">83%</a>) and <a href="http://www.axios.com/men-still-run-venture-capital-2342539558.html">93%</a> of VC decision-makers are male, so diversity on boards begins at a deficit. Independent director seats often go unfilled at the outset and, later, are often filled in haste, closing a critical window of opportunity. Instead, declare an independent seat at the board’s first formation, actively move to fill it and don’t do so without interviewing at least one female candidate. If you can’t find at least one via your network, quickly go to retained search. Rinse and repeat whenever filling an independent seat.</p><p><strong>Embrace the “Q” word. </strong>Quotas work. Set a hard target that 30% to 50% of your board will be non-white male within two years of formation. Diversity breeds diversity, and racial and gender diversity go hand-in-hand. In Europe, where Norway, Germany, France and Spain have legally mandated quotas for corporate boards, the data show that <a href="http://european.ewob-network.eu/wp-content/uploads/2016/04/EWoB-quant-report-WEB-spreads.pdf">diversity is on the rise</a> (much faster than in the U.S.) and that the conversation around women in the workforce is changing too, including within companies.</p><p><strong>Impose term limits. </strong>Investors with preferred status have a contractual right to a board seat, which naturally limits board construction. Don’t further constrain a board by setting long-term service expectations for the others. Instead, create a norm for finite terms and natural board succession. Set three-year terms for all non-contractual seats. This doesn’t just support diversity — data show that a mix of institutional energy, fresh eyes and new skill sets are <a href="http://www.scientificamerican.com/article/how-diversity-makes-us-smarter/">positively affect a company’s performance</a>. Public companies typically have set terms and private companies can institutionalize the same.</p><p><strong>Choose expertise over optics. </strong>During the IPO window in particular, companies feel pressure to quickly augment the skill sets and optics value of their boards. This can turbocharge the “buddy network” effect for convenience and also skew for candidates with some perceived cachet. Instead, choose expertise over optics. For example, finance experts for the audit committee are in particularly high demand. Companies can prioritize bringing a woman into that director slot, given that the functional expertise is found in a range of sectors. Companies can also widen the search aperture beyond the C-suite as we wait for those ranks to become more representative. Many corporate VPs from mature companies or leaders from public and not-for-profit sectors bring broad operating experience, including managing large organizations and budgets.</p><p><strong>Engage a search firm. </strong>Companies have a tendency to deliberately avoid retained search. Leveraging existing networks and championing frugality are VCs’ mandates, but if your network is just more people like you, that’s not going to help diversity. When the pressure to fill slots mounts and there is no diversity strategy, the risk of default-to-dude through known networks is high. Search firms, by contrast, are stepping up the diversity game, expanding and curating the growing databases of female talent.</p><p><strong>Extend an invitation. </strong>While I commend efforts to corral talented board candidates through databases and to create new networks via training programs, such as <a href="http://theboardlist.com/">Boardlist</a>, <a href="http://www.csweetener.org/">CSweetener</a>, and <a href="http://www.womeninbio.org/executives/boardroom-ready">Boardroom Ready</a>, my view is that our problem is one of demand, not supply. I encounter immensely talented women every day, any of whom would be of enormous service to company boards. I am puzzled why they — unlike their male peers — need to be groomed or trained for the role. What they actually need is the first invitation. Extend it.</p><p>A lot of the conversation about increasing diversity is about finding women. But we also need to talk about what it takes to make a company and board a club that a talented woman wants to join. As demand for women executives and directors continues to grow, there will be increased competition to land them.</p><p>At <a href="http://www.canaan.com/">Canaan</a>, we are reaching a tipping point, with women making up 40% of our General Partner ranks and 40% of all investment professionals. Women around the table — and at its head — is what we’ve come to expect and embrace. It’s our new “normal”, and it is better: not only for us, but for the companies we serve.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a5e011135f54" width="1" height="1" alt=""><hr><p><a href="https://medium.com/canaan-partners/the-roadmap-for-increasing-diversity-in-boardrooms-a5e011135f54">The Roadmap for Increasing Diversity in Boardrooms</a> was originally published in <a href="https://medium.com/canaan-partners">Canaan</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Promotion and Growth in Canaan’s Healthcare Practice]]></title>
            <link>https://medium.com/canaan-partners/promotion-and-growth-in-canaans-healthcare-practice-6d4c4819ce7f?source=rss-c1d9c296707f------2</link>
            <guid isPermaLink="false">https://medium.com/p/6d4c4819ce7f</guid>
            <category><![CDATA[promotion]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Nina Kjellson]]></dc:creator>
            <pubDate>Mon, 26 Sep 2016 18:45:22 GMT</pubDate>
            <atom:updated>2016-09-26T18:45:22.298Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*NowfplWLF_qp0kLEevqMGg.png" /><figcaption>Julie Papanek, Partner; Colleen Cuffaro, Principal</figcaption></figure><p>I joined Canaan a year ago because I was compelled by the people — not just a group of talented investors but also a team that spent time thinking about how best to build a world class organization, in addition to a high-performing portfolio. I’ve spent the last year getting to know Canaan’s diverse, multigenerational team, it’s four offices spanning Connecticut, New York, Menlo Park and now San Francisco (!). In the way we collaborate, communicate and cheer each other on, I can absolutely say I joined not just a firm but a family. So, it is especially gratifying to celebrate two promotions on our healthcare team: Julie Papanek to Partner and Colleen Cuffaro to Principal. And, yes Ventureland: Canaan has not just one — or even two — but <em>FIVE</em> women investors. And as of today, four women partners. Woot.</p><p>Julie, based in Menlo Park and San Francisco, joined Canaan 3 years ago after receiving her MBA at Stanford. Prior to her years on The Farm, Julie earned her operating stripes at Genentech. From 2006 to 2011, she led cross-functional teams focused on discovering and developing high-impact drugs and then shifted her focus to launching, commercializing, and helping patients afford new cancer therapies. Like many on the Canaan team, Julie is no stranger to technical degrees with a Masters from Cambridge’s Biotechnology Institute and an undergraduate degree in biophysics and biochemistry from Yale (can you say “slouch”?). Being a connector at heart, Julie has built an incredible network of entrepreneurs and executives from her days at GSB and Genentech and those she is meeting day-to-day as a venture capitalist. She is thoughtful with advice and feedback, making her a great thought-partner for start-ups in biopharma and digital health, her sectors of focus. Julie actively co-sponsored Canaan’s investments in Chrono, CytomX, Glooko, Unchained Labs, and Truveris and has been making fast marks as a deal-doer in her own right, too. In fact, she is setting some records with her timelines from initial funding to exit: Cellular Research was acquired within 20 months of our seed investment and Protagonist IPO’d one year after Julie led their Series C (no pressure, venture colleagues). Outside of Canaan, her passions are fitness, travel, sailing, good food and community. A big-hearted go-getter, we can’t wait to see what Julie comes up with next. (If this reads like a dating site profile, spoiler alert: she got taken off the market last week!)</p><p>Colleen Cuffaro is based in Westport, CT. She joined Canaan in June of 2014 after getting a PhD in cellular and molecular physiology at Yale and, before then, spending three as an analytical chemist at a contract manufacturing organization. As a graduate student focused on metabolism, Colleen immersed herself in the community at Yale, both in her lab and department as well as the broader university community. She came quickly to the decision that her career would focus on drug development and not academia but, ever the well-rounded person, she took on not just her thesis, but also the biotech club, cycling and triathlon clubs, various internships and teaching. It is through her curiosity and initiative, that Colleen met Tim Shannon, one of our GP’s, when he spoke at Yale about one of our start-ups. With a little nudging from Tim, Colleen decided to merge her drug development passion with early-stage venture capital. Since joining, she has supported various biopharma investments (Antiva, Vivace, Spyrx, Ideaya and NextCure), helping the Canaan team with due diligence and the companies by providing operating support. With a clear knack for start-up work, she just seeded a brand new biotech company and is serving as its interim CEO. We are keeping the company stealth for now but it would be a lucky guess that it leverages her (and Canaan’s) strong ties to Yale. It is a novel approach to a very difficult and important problem — a spot on match for Colleen’s investment style. Much like her multi-disciplinary approach to venture, it shouldn’t come as no surprise that Colleen is also a multi-sport athlete in her free time: an Iron(wo)man triathlete, no less. So if you don’t find Colleen in the halls of various East Coast universities, working on spinning out IP, look for her on a bike or in a pool around Westport. But do look for her. She is well worth getting to know.</p><p>As you can tell, I/we are proud as can be to celebrate Julie’s and Colleen’s promotions and we look forward to witnessing and supporting their continued success as key members of the Canaan family.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6d4c4819ce7f" width="1" height="1" alt=""><hr><p><a href="https://medium.com/canaan-partners/promotion-and-growth-in-canaans-healthcare-practice-6d4c4819ce7f">Promotion and Growth in Canaan’s Healthcare Practice</a> was originally published in <a href="https://medium.com/canaan-partners">Canaan</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>